Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib added to standard primary therapy in elderly patients with newly diagnosed acute myeloid leukemia
2005-005966-35Phase 2Completed
- Sponsor
- Universitätsklinikum Münster
- Start
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Sorafenib plus standard primary therapy with Placebo plus standard primary therapy (2 arms). Primary endpoints: Event-free survival and Event-free survival in FLT3-mutated patients. Started Feb 2006; status: completed.
02
Drugs
sorafenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2005-005966-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005966-35.